By when must interventional clinical trials be registered according to the FDAAA?

By when must interventional clinical trials be registered according to the FDAAA?

• A. Before enrollment on ClinicalTrials.gov
• B. Before data analysis begins
• C. Before results are published
• D. After patient recruitment is completed

Answer: (A)

The correct choice emphasizes the requirement set by the Food and Drug Administration Amendments Act (FDAAA), which mandates that interventional clinical trials must be registered on ClinicalTrials.gov before participant enrollment begins. This regulation is designed to promote transparency and accountability in clinical research, ensuring that trials are publicly documented prior to any subjects being recruited. By requiring registration at this stage, the FDA aims to reduce selective reporting and enhance the integrity of clinical trial data, ultimately protecting public health and contributing to the body of scientific knowledge. In this context, the other options do not align with the regulatory requirements as outlines by the FDAAA. For example, registering before data analysis or results publication would not provide the same level of preemptive transparency and may lead to biases if trials were selectively published after the outcome was known. Similarly, registering after patient recruitment would negate the purpose of ensuring that potential participants are aware of the trial and its purpose prior to being approached for inclusion.

The correct choice emphasizes the requirement set by the Food and Drug Administration Amendments Act (FDAAA), which mandates that interventional clinical trials must be registered on ClinicalTrials.gov before participant enrollment begins. This regulation is designed to promote transparency and accountability in clinical research, ensuring that trials are publicly documented prior to any subjects being recruited. By requiring registration at this stage, the FDA aims to reduce selective reporting and enhance the integrity of clinical trial data, ultimately protecting public health and contributing to the body of scientific knowledge.

In this context, the other options do not align with the regulatory requirements as outlines by the FDAAA. For example, registering before data analysis or results publication would not provide the same level of preemptive transparency and may lead to biases if trials were selectively published after the outcome was known. Similarly, registering after patient recruitment would negate the purpose of ensuring that potential participants are aware of the trial and its purpose prior to being approached for inclusion.